Ranbaxy receives USFDA's nod for pain relief
Ranbaxy Laboratories to manufacture and market Hydrocodone Bitartrate and Acetaminophen tablets in the US.
By INDIATIMES NEWS NETWORK |
GURGAON: Pharma major Ranbaxy Laboratories Limited (RLL) has received approval from the US Food and Drug Administration to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP in variable strengths.
"Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the relief of moderate to moderately severe pain and Ranbaxy is pleased to receive final FDA approval for multiple strengths of this product. These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period to all classes of trade," according to Jim Meehan, Vice President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc.
Ranbaxy will manufacture and market the tablet in dosages of 7.5 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg. Total annual market sales for Hydrocodone Bitartrate and Acetaminophen Tablets were $390.6 million.
"Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the relief of moderate to moderately severe pain and Ranbaxy is pleased to receive final FDA approval for multiple strengths of this product. These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period to all classes of trade," according to Jim Meehan, Vice President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc.
Ranbaxy will manufacture and market the tablet in dosages of 7.5 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg. Total annual market sales for Hydrocodone Bitartrate and Acetaminophen Tablets were $390.6 million.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
